Semaglutide and Vascular Regeneration

NCT05870462 on ClinicalTrials.gov · last registry update 2023-07-25

100 participants. Its estimated completion date, December 2024, has passed with no update to the record. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for cardiovascular disease and obesity, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Canadian Medical and Surgical Knowledge Translation Research Group
Sponsor type: Other
Enrollment: 100
Started: 2023-04-29
Primary completion: 2024-12 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Changes in the mean frequency (%) of circulating ALDHhiSSClow primitive progenitor cells in individuals treated with semaglutide versus usual care for 6 months

Conditions studied

Atherosclerosis · Cardiovascular Diseases · Diabetes Mellitus, Type 2 · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.